Sunovion Pharmaceuticals has presented results from three studies of Brovana arformoterol tartrate inhalation solution for the treatment of COPD at ATS 2015.
According to Sunovion, the studies show that Brovana produces clinically significant improvement in health status compared to placebo, that only about half of COPD patients in hospital get long acting bronchodilators while hospitalized, and that a third of COPD patients have little confidence in correct delivery device technique.
A poster titled “Improvements in Health Status for Individuals with COPD Treated With Nebulized Arformoterol Tartrate: Results from a 52-Week Trial” presents data from a double blind, parallel-group, placebo-controlled, randomized trial that gathered patient reported health information at 3, 6, and 12 months, finding that 38.3% of patients using Brovana reported significantly higher scores on a health questionnaire at 12 months compared to 30.8% of patients treated with the placebo.
Noting that the majority of the patients who reported a lack of confidence in their device technique also had low adherence, Sunovion Respiratory Group Director, Health Economics and Outcomes Research, Vamsi Bollu commented, “Findings from this analysis further demonstrate the importance of confidence in COPD device use and suggest that a switch to a different device, such as a nebulizer, should be considered for some patients.”
Read the Sunovion press release.
